[
{
"abbr":"2-h PG",
"description":"2-h plasma glucose"
},
{
"abbr":"ACCORD-MIND",
"description":"Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes"
},
{
"abbr":"ACIP",
"description":"Advisory Committee on Immunization Practices"
},
{
"abbr":"ACOG",
"description":"American College of Obstetricians and Gynecologists"
},
{
"abbr":"AD",
"description":"Autosomal dominant"
},
{
"abbr":"ADA",
"description":"American Diabetes Association"
},
{
"abbr":"AHEAD",
"description":"Action For Health in Diabetes"
},
{
"abbr":"AIDS",
"description":"Acquired immunodeficiency syndrome"
},
{
"abbr":"AR",
"description":"Autosomal recessive"
},
{
"abbr":"ARB",
"description":"Angiotensin receptor blocker"
},
{
"abbr":"ARV",
"description":"Antiretroviral"
},
{
"abbr":"ASCVD",
"description":"Atherosclerotic cardiovascular disease"
},
{
"abbr":"A1C",
"description":"Glycated hemoglobin"
},
{
"abbr":"BMD",
"description":"Bone mineral density"
},
{
"abbr":"BMI",
"description":"Body mass index"
},
{
"abbr":"BRFSS",
"description":"The Behavioral Risk Factor Surveillance System"
},
{
"abbr":"CCM",
"description":"Chronic care model"
},
{
"abbr":"CDC",
"description":"Centers for Disease Control and Prevention"
},
{
"abbr":"CFRD",
"description":"Cystic fibrosisײelated diabetes"
},
{
"abbr":"CGM",
"description":"Continuous glucose monitoring"
},
{
"abbr":"CHF",
"description":"Congestive heart failure"
},
{
"abbr":"CHW",
"description":"Community health worker"
},
{
"abbr":"CHWs",
"description":"Community health workers"
},
{
"abbr":"CKD",
"description":"Chronic kidney disease"
},
{
"abbr":"CVD",
"description":"Cardiovascular disease"
},
{
"abbr":"CVOT",
"description":"Cardiovascular outcomes trial"
},
{
"abbr":"DCCT",
"description":"Diabetes Control and Complications Trial"
},
{
"abbr":"DKA",
"description":"Diabetic ketoacidosis"
},
{
"abbr":"DM",
"description":"Diabetes mellitus"
},
{
"abbr":"DPP",
"description":"Diabetes Prevention Program"
},
{
"abbr":"DSMES",
"description":"Diabetes self-management education and support"
},
{
"abbr":"eGFR",
"description":"Estimated glomerular filtration rate"
},
{
"abbr":"FDA",
"description":"Food and Drug Administration"
},
{
"abbr":"FI",
"description":"Food insecurity"
},
{
"abbr":"FPG",
"description":"Fasting plasma glucose"
},
{
"abbr":"FRAX",
"description":"Fracture risk assessment tool"
},
{
"abbr":"GDM",
"description":"Gestational diabetes mellitus"
},
{
"abbr":"GLT",
"description":"Glucose load test"
},
{
"abbr":"HAPO",
"description":"Hyperglycemia and Adverse Pregnancy Outcome"
},
{
"abbr":"HDL",
"description":"High-density lipoprotein"
},
{
"abbr":"HIV",
"description":"Human immunodeficiency virus"
},
{
"abbr":"HOMA",
"description":"Homeostatic model assessment"
},
{
"abbr":"IADPSG",
"description":"International Association of the Diabetes and Pregnancy Study Groups"
},
{
"abbr":"IFG",
"description":"Impaired fasting glucose"
},
{
"abbr":"IGT",
"description":"Impaired glucose tolerance"
},
{
"abbr":"INS",
"description":"Insulin gene"
},
{
"abbr":"IPEX",
"description":"Immunodysregulation, polyendocrinopathy, enteropathy X-linked"
},
{
"abbr":"IUGR",
"description":"Intrauterine growth restriction"
},
{
"abbr":"LDL",
"description":"Low-density lipoprotein"
},
{
"abbr":"MACE",
"description":"Major adverse cardiac event"
},
{
"abbr":"MNT",
"description":"Medical nutrition therapy"
},
{
"abbr":"MODY",
"description":"Maturity-onset diabetes of the young"
},
{
"abbr":"NADAC",
"description":"National Average Drug Acquisition Cost"
},
{
"abbr":"NDDG",
"description":"National Diabetes Data Group"
},
{
"abbr":"NGSP",
"description":"National Glycohemoglobin Standardization Program"
},
{
"abbr":"NHANES",
"description":"National Health and Nutrition Examination Survey"
},
{
"abbr":"NHIS",
"description":"National Health Interview Survey"
},
{
"abbr":"NIH",
"description":"National Institutes of Health"
},
{
"abbr":"NODAT",
"description":"New-onset diabetes after transplantation"
},
{
"abbr":"NRTIs",
"description":"Nucleoside reverse transcriptase inhibitors"
},
{
"abbr":"OGTT",
"description":"Oral glucose tolerance test"
},
{
"abbr":"PAD",
"description":"Peripheral arterial disease"
},
{
"abbr":"Pis",
"description":"Protease inhibitors"
},
{
"abbr":"PPC",
"description":"Professional Practice Committee"
},
{
"abbr":"PPSV23",
"description":"23-valent pneumococcal polysaccharide vaccine"
},
{
"abbr":"PTDM",
"description":"Posttransplantation diabetes mellitus"
},
{
"abbr":"RCAD",
"description":"Renal cysts and diabetes"
},
{
"abbr":"UL",
"description":"Upper limit"
},
{
"abbr":"WHO",
"description":"World Health Organization"
},
{
"abbr":"DD",
"description":"Diabetes distress"
},
{
"abbr":"DPPOS",
"description":"Diabetes Prevention Program Outcomes Study"
},
{
"abbr":"DASH",
"description":"Dietary Approaches to Stop Hypertension"
},
{
"abbr":"ALA",
"description":"Alpha-linolenic acid"
},
{
"abbr":"EPA",
"description":"Eicosapentaenoic acid"
},
{
"abbr":"DHA",
"description":"Docosahexaenoic acid"
},
{
"abbr":"DPS",
"description":"Diabetes Prevention Study"
},
{
"abbr":"CMS",
"description":"Centers for Medicare and Medicaid Services"
},
{
"abbr":"DPRP",
"description":"Diabetes Prevention Recognition Program"
},
{
"abbr":"GLP",
"description":"Glucagon-like peptide"
},
{
"abbr":"VADT",
"description":"Veterans Affairs Diabetes Trial"
},
{
"abbr":"ADAG",
"description":"International A1C Derived Average Glucose"
},
{
"abbr":"UKPDS",
"description":"UK Prospective Diabetes Study"
},
{
"abbr":"EDIC",
"description":"Epidemiology of Diabetes Interventions and Complications"
},
{
"abbr":"MI",
"description":"Myocardial infarction"
},
{
"abbr":"RYGB",
"description":"Roux-en-Y gastric bypass"
},
{
"abbr":"GI",
"description":"Gastrointestinal"
},
{
"abbr":"FBG",
"description":"Fasting blood glucose"
},
{
"abbr":"CSII",
"description":"Continuous subcutaneous insulin infusion"
},
{
"abbr":"PPAR-γ",
"description":"Peroxisome proliferator–activated receptor  γ"
},
{
"abbr":"DKD",
"description":"Diabetic kidney disease"
},
{
"abbr":"IR",
"description":"Immediate release"
},
{
"abbr":"ER",
"description":"Extended release"
},
{
"abbr":"GIP",
"description":"Glucose-dependent insulinotropic peptide"
},
{
"abbr":"GRADE",
"description":"Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study"
},
{
"abbr":"JDRF",
"description":"Juvenile Diabetes Research Foundation"
},
{
"abbr":"eGFR",
"description":"Estimated glomerular filtration rate"
},
{
"abbr":"AWP",
"description":"Average wholesale prices"
},
{
"abbr":"SQ",
"description":"Subcutaneous"
},
{
"abbr":"NASH",
"description":"Nonalcoholic steatohepatitis"
},
{
"abbr":"XL",
"description":"Extended release"
},
{
"abbr":"FEV-1",
"description":"Forced expiratory volume in one second"
},
{
"abbr":"SGLT2",
"description":"Sodium–glucose cotransporter 2"
},
{
"abbr":"ELIXA",
"description":"Evaluation of Lixisenatide in Acute Coronary Syndrome"
},
{
"abbr":"HR",
"description":"Hazard ratio"
},
{
"abbr":"LEADER",
"description":"The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsdA Long Term Evaluation"
},
{
"abbr":"TECOS",
"description":"Trial Evaluating Cardiovascular Outcomes with Sitagliptin"
},
{
"abbr":"EXSCEL",
"description":"Exenatide Study of Cardiovascular Event Lowering"
},
{
"abbr":"LIPID",
"description":"The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus"
},
{
"abbr":"AIM-HIGH",
"description":"The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes"
},
{
"abbr":"IMPROVE-IT",
"description":"The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial"
},
{
"abbr":"HOT",
"description":"Hypertension optimal treatment"
},
{
"abbr":"PCSK",
"description":"Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification"
},
{
"abbr":"EMPA-REG",
"description":"(Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients"
},
{
"abbr":"RR",
"description":"Relative risk"
},
{
"abbr":"CETP",
"description":"Cholesteryl ester transfer protein"
},
{
"abbr":"BI",
"description":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk"
},
{
"abbr":"HPS",
"description":"Heart Protection Study"
},
{
"abbr":"BP",
"description":"Blood pressure"
},
{
"abbr":"CANVAS",
"description":"Canagliflozin Cardiovascular Assessment Study"
},
{
"abbr":"GE",
"description":"Urinary albumin–to–creatinine ratio"
},
{
"abbr":"ST",
"description":"Acute kidney injury"
},
{
"abbr":"ACE",
"description":"Angiotensin converting enzyme"
},
{
"abbr":"ECG",
"description":"Electrocardiogram"
},
{
"abbr":"HPS2-THRIVE",
"description":"Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events"
},
{
"abbr":"REG",
"description":"Acute coronary syndrome"
},
{
"abbr":"TIMI",
"description":"Thrombolysis in Myocardial Infarction"
},
{
"abbr":"AGENTS",
"description":"The Action to Control Cardiovascular Risk in Diabetes blood pressure"
},
{
"abbr":"CHD",
"description":"Coronary heart disease"
}
]